These researchers found that after ex vivo treatment, the first group had better long-term primary tumor control and survival and an increased expansion of peripheral antigen-specific CD8 T cells, tumor-infiltrating NK cells, and IFN production. The gene discussed is CD8A; the disease is neoplasm.